45 results
Page 2 of 3
8-K
EX-99.1
rizjf6 pmt
8 Sep 23
Material Modifications to Rights of Security Holders
5:05pm
8-K
EX-99.1
2jas96naf8
5 Sep 23
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones
7:06am
8-K
EX-99.1
qjs7bayn2cb6iar96
23 Jun 23
Entry into a Material Definitive Agreement
9:16am
8-K
a88fbq
23 Jun 23
Entry into a Material Definitive Agreement
9:16am
PRE 14A
imr43w2zy8ut
7 Apr 23
Preliminary proxy
4:02pm
8-K
ft208rimg
16 Nov 21
Departure of Directors or Certain Officers
7:01am
8-K
EX-99.1
xdh5g8abpb6mwa8
5 Aug 21
Aeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights
8:30am
8-K
ok5nd6 kq5er
22 Jun 21
Departure of Directors or Certain Officers
8:30am
8-K
EX-99.2
a8zd42c 4dagb
18 Mar 21
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights
8:31am
8-K
EX-99.1
hijrdicyc6 i3
5 Jan 21
Regulation FD Disclosure
8:30am
8-K
EX-99.1
0zp3pt cd
10 Aug 20
Aeglea BioTherapeutics Reports Second Quarter 2020 Financial Results and Corporate Highlights
8:30am
8-K
EX-99.1
9z4bg1w7wz yvma01
27 Apr 20
Regulation FD Disclosure
4:18pm
8-K
EX-99.1
2vazff75eb
24 Feb 20
Aeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent Milestones
7:30am
8-K
EX-99.2
s6hjc 56r92687eykja
13 Jan 20
Company Expects to Initiate a Phase 1/2 Trial in the Second Quarter of 2020
7:01am
8-K
EX-99.1
a12ufuu
3 Dec 19
Regulation FD Disclosure
8:00am